Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males
Patrick G. Clay, Maqual R. Graham, Cameron C. Lindsey, Kenneth C. Lamp, Collin Freeman, Alan Glaros
Dive into the research topics of 'Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males'. Together they form a unique fingerprint.